董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jean Luc Butel | 男 | Director | 69 | 4.52万美元 | 37.91 | 2025-10-23 |
| Abraham Bassan | 男 | Director | 40 | 18.26万美元 | 未持股 | 2025-10-23 |
| Mir Imran | 男 | Chairman, Director | 69 | 5.33万美元 | 2292.69 | 2025-10-23 |
| Dennis Ausiello | 男 | Director | 79 | 4.38万美元 | 27.20 | 2025-10-23 |
| Talat Imran | 男 | Director, Chief Executive Officer | 44 | 105.21万美元 | 192.03 | 2025-10-23 |
| Lisa Rometty | 女 | Director | 57 | 4.66万美元 | 21.64 | 2025-10-23 |
| Vasudev Bailey | 男 | Director | 41 | 18.38万美元 | 未持股 | 2025-10-23 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Talat Imran | 男 | Director, Chief Executive Officer | 44 | 105.21万美元 | 192.03 | 2025-10-23 |
| Svai Sanford | 男 | Chief Financial Officer | 55 | 94.64万美元 | 66.83 | 2025-10-23 |
| Mir Hashim | 男 | Chief Scientific Officer | 66 | 129.15万美元 | 87.43 | 2025-10-23 |
| Eric Groen | 男 | General Counsel | 54 | 未披露 | 未持股 | 2025-10-23 |
| Kate McKinley | 女 | Chief Business Officer | 48 | 94.39万美元 | 未持股 | 2025-10-23 |
董事简历
中英对照 | 中文 | 英文- Jean Luc Butel
-
Jean Luc Butel，2016年6月至2019年6月担任Takeda的外部董事和审计和监督委员会成员。他于2019年6月被任命为外部董事，不是Takeda的审计和监督委员会成员。他有提供肾脏和医院产品组合的医疗保健公司百特国际公司的职位：国际总裁（2015年1月至2015年6月）；公司运营总监，公司副总裁兼国际总裁（2012年2月） （2014年12月）。医疗技术领域的全球领导者美敦力公司的职位：公司官员，执行委员会成员，执行副总裁；国际集团总裁（2011年1月至2012年1月）；美敦力国际公司执行官，执行委员会委员，高级副总裁兼总裁（2008年5月至2010年12月）；美敦力公司行政总监，执行委员会委员，高级副总裁兼总裁亚太地区（2003年8月至2008年4月）。他在加入美敦力公司之前，在1991年到1999年担任过迪金森公司各种各样的领导角色后，担任独立技术、强生公司总裁。
Jean Luc Butel served as External Director and member of the Audit and Supervisory Committee of Takeda from June 2016 to June 2019, and as External Director who is not a member of the Audit and Supervisory Committee of Takeda from June 2019 to June 2024. He was appointed External Director who is a member of the Audit and Supervisory Committee of Takeda in June 2024. He currently also serves as Global Healthcare Advisor, President of K8 Global Pte. Ltd., and External Director of Rani Therapeutics. Mr. Butel previously served as External Director of Novo Holdings A/S, President, International, Corporate Vice President and Operating Committee Member of Baxter International Inc. and has held leadership positions at Medtronic, Inc., Johnson & Johnson, Becton, Dickinson and Company and Nippon Becton Dickinson Company, Ltd. - Jean Luc Butel，2016年6月至2019年6月担任Takeda的外部董事和审计和监督委员会成员。他于2019年6月被任命为外部董事，不是Takeda的审计和监督委员会成员。他有提供肾脏和医院产品组合的医疗保健公司百特国际公司的职位：国际总裁（2015年1月至2015年6月）；公司运营总监，公司副总裁兼国际总裁（2012年2月） （2014年12月）。医疗技术领域的全球领导者美敦力公司的职位：公司官员，执行委员会成员，执行副总裁；国际集团总裁（2011年1月至2012年1月）；美敦力国际公司执行官，执行委员会委员，高级副总裁兼总裁（2008年5月至2010年12月）；美敦力公司行政总监，执行委员会委员，高级副总裁兼总裁亚太地区（2003年8月至2008年4月）。他在加入美敦力公司之前，在1991年到1999年担任过迪金森公司各种各样的领导角色后，担任独立技术、强生公司总裁。
- Jean Luc Butel served as External Director and member of the Audit and Supervisory Committee of Takeda from June 2016 to June 2019, and as External Director who is not a member of the Audit and Supervisory Committee of Takeda from June 2019 to June 2024. He was appointed External Director who is a member of the Audit and Supervisory Committee of Takeda in June 2024. He currently also serves as Global Healthcare Advisor, President of K8 Global Pte. Ltd., and External Director of Rani Therapeutics. Mr. Butel previously served as External Director of Novo Holdings A/S, President, International, Corporate Vice President and Operating Committee Member of Baxter International Inc. and has held leadership positions at Medtronic, Inc., Johnson & Johnson, Becton, Dickinson and Company and Nippon Becton Dickinson Company, Ltd.
- Abraham Bassan
-
Abraham Bassan自2020年6月以来一直担任我们的董事会成员。自2017年7月以来，Bassan先生一直担任Samsara Biocapital的副总裁。在加入Samsara Biocapital之前，Bassan先生于2015年10月至2017年7月担任RevolutionMedicines，Inc.的项目生物学总监，并于2014年12月至2015年9月担任其项目管理总监。Bassan先生于2012年9月至2014年9月担任Aurora Medical，Inc.的创始人兼首席执行官。从2010年5月到2012年8月，Bassan先生还担任bluebirdbio，Inc.的项目开发副总监。Bassan先生拥有普林斯顿大学分子生物学学士学位和斯坦福大学发展生物学硕士学位。
Abraham Bassan,has served as a member of Septerna, Inc. board of directors since November 2021. Since April 2021, Mr. Bassan has served as a Principal at Samsara, a privately held life science investment firm, where he served as a Vice President from July 2017 to April 2021. Since May 2022, Mr. Bassan has served as the interim CEO, President and a Director at Link Cell Therapies Inc., a privately held biotechnology company. From February 2021 to May 2022, Mr. Bassan served as President of Cargo Therapeutics, Inc. (Nasdaq: CRGX), a then privately held clinical-stage cell therapies company (Cargo Therapeutics). Prior to that, from December 2014 to July 2017, Mr. Bassan served as Director of Program Biology at Revolution Medicines, Inc. (Nasdaq: RVMD), a then privately held oncology company. Prior to that, from September 2012 to September 2014, Mr. Bassan served as the founder and Chief Executive Officer of Aurora Medical, Inc., a privately held molecular diagnostics testing services company. From 2010 to 2012, Mr. Bassan served as an Associate Director of Program Management at bluebird bio, Inc. (Nasdaq: BLUE) (bluebird bio), a then privately held biotechnology company, where he was the Project Manager for several of the company's gene therapy programs. Earlier in his career, Mr. Bassan was an Associate at Third Rock Ventures, where he played a leading role in the firm's investment in bluebird bio, as well as the ideation of Blueprint Medicines Corporation (Nasdaq: BPMC), a publicly traded precision medicine oncology company. Mr. Bassan currently serves on the board of directors of Cargo Therapeutics. Mr. Bassan previously served on the board of directors of Graphite Bio, Inc. (merged with LENZ Therapeutics, Inc. (Nasdaq: LENZ)), from June 2020 to March 2024, and on the boards of directors of numerous privately held biotechnology companies. Mr. Bassan obtained his B.A. in Molecular Biology from Princeton University and his M.S. in Developmental Biology from Stanford University. - Abraham Bassan自2020年6月以来一直担任我们的董事会成员。自2017年7月以来，Bassan先生一直担任Samsara Biocapital的副总裁。在加入Samsara Biocapital之前，Bassan先生于2015年10月至2017年7月担任RevolutionMedicines，Inc.的项目生物学总监，并于2014年12月至2015年9月担任其项目管理总监。Bassan先生于2012年9月至2014年9月担任Aurora Medical，Inc.的创始人兼首席执行官。从2010年5月到2012年8月，Bassan先生还担任bluebirdbio，Inc.的项目开发副总监。Bassan先生拥有普林斯顿大学分子生物学学士学位和斯坦福大学发展生物学硕士学位。
- Abraham Bassan,has served as a member of Septerna, Inc. board of directors since November 2021. Since April 2021, Mr. Bassan has served as a Principal at Samsara, a privately held life science investment firm, where he served as a Vice President from July 2017 to April 2021. Since May 2022, Mr. Bassan has served as the interim CEO, President and a Director at Link Cell Therapies Inc., a privately held biotechnology company. From February 2021 to May 2022, Mr. Bassan served as President of Cargo Therapeutics, Inc. (Nasdaq: CRGX), a then privately held clinical-stage cell therapies company (Cargo Therapeutics). Prior to that, from December 2014 to July 2017, Mr. Bassan served as Director of Program Biology at Revolution Medicines, Inc. (Nasdaq: RVMD), a then privately held oncology company. Prior to that, from September 2012 to September 2014, Mr. Bassan served as the founder and Chief Executive Officer of Aurora Medical, Inc., a privately held molecular diagnostics testing services company. From 2010 to 2012, Mr. Bassan served as an Associate Director of Program Management at bluebird bio, Inc. (Nasdaq: BLUE) (bluebird bio), a then privately held biotechnology company, where he was the Project Manager for several of the company's gene therapy programs. Earlier in his career, Mr. Bassan was an Associate at Third Rock Ventures, where he played a leading role in the firm's investment in bluebird bio, as well as the ideation of Blueprint Medicines Corporation (Nasdaq: BPMC), a publicly traded precision medicine oncology company. Mr. Bassan currently serves on the board of directors of Cargo Therapeutics. Mr. Bassan previously served on the board of directors of Graphite Bio, Inc. (merged with LENZ Therapeutics, Inc. (Nasdaq: LENZ)), from June 2020 to March 2024, and on the boards of directors of numerous privately held biotechnology companies. Mr. Bassan obtained his B.A. in Molecular Biology from Princeton University and his M.S. in Developmental Biology from Stanford University.
- Mir Imran
-
Mir Imran创立了Rani Therapeutics，LLC，自2012年2月起担任董事会成员。从2012年2月到2021年6月，他担任我们的总裁兼首席执行官，并从2021年6月开始担任我们的执行主席。自2012年11月起，Imran先生担任Incube Ventures，LP和Incube众筹，LLC（医疗保健领域的风险投资公司）的联合创始人和董事总经理。自1995年以来，Imran先生还担任Incube Labs，LLC（他创立的研究公司）的董事长。Imran先生是美国医学和生物工程师学会、美国国家工程院和美国发明家学会的研究员。伊姆兰在罗格斯大学获得电气工程学士学位，并在罗格斯医学院就读。
Mir Imran,founded Rani Therapeutics, LLC and has served as a member of Board of Directors since February 2012. From February 2012 to June 2021, he served as President and Chief Executive Officer, and since June 2021, as Chairman. Since November 2012, Mr. Imran has served as a co-founder and a Managing Director of InCube Ventures, LP and InCube Crowdfunding, LLC, venture capital companies in the healthcare sector. Since 1995, Mr. Imran has also served as the Chairman of InCube Labs, LLC, a research company that he founded. Mr. Imran is a fellow of the American Institute of Medical and Biological Engineers, the National Academy of Engineering and the National Academy of Inventors. Mr. Imran earned a B.S. in Electrical Engineering from Rutgers University, and attended Rutgers Medical School. - Mir Imran创立了Rani Therapeutics，LLC，自2012年2月起担任董事会成员。从2012年2月到2021年6月，他担任我们的总裁兼首席执行官，并从2021年6月开始担任我们的执行主席。自2012年11月起，Imran先生担任Incube Ventures，LP和Incube众筹，LLC（医疗保健领域的风险投资公司）的联合创始人和董事总经理。自1995年以来，Imran先生还担任Incube Labs，LLC（他创立的研究公司）的董事长。Imran先生是美国医学和生物工程师学会、美国国家工程院和美国发明家学会的研究员。伊姆兰在罗格斯大学获得电气工程学士学位，并在罗格斯医学院就读。
- Mir Imran,founded Rani Therapeutics, LLC and has served as a member of Board of Directors since February 2012. From February 2012 to June 2021, he served as President and Chief Executive Officer, and since June 2021, as Chairman. Since November 2012, Mr. Imran has served as a co-founder and a Managing Director of InCube Ventures, LP and InCube Crowdfunding, LLC, venture capital companies in the healthcare sector. Since 1995, Mr. Imran has also served as the Chairman of InCube Labs, LLC, a research company that he founded. Mr. Imran is a fellow of the American Institute of Medical and Biological Engineers, the National Academy of Engineering and the National Academy of Inventors. Mr. Imran earned a B.S. in Electrical Engineering from Rutgers University, and attended Rutgers Medical School.
- Dennis Ausiello
-
Dennis Ausiello自2018年9月起担任我们的董事会成员。Ausiello博士担任评估技术和持续健康控制中心的主任，该中心是他共同创立的，哈佛医学院杰克逊临床医学特聘教授和麻省总医院荣休医师。从1996年到2013年4月，Ausiello博士担任麻省总医院的首席医疗官。Ausiello博士是美国国家科学院医学研究所的成员和美国艺术与科学院院士。Ausiello博士自2012年4月起担任AlnylamPharmaceuticals，Inc.（一家RNA干扰公司）的董事会成员，自2015年4月起担任赛里斯治疗公司（一家微生物群治疗公司）的董事会成员，此前曾担任辉瑞公司（一家制药公司）的董事会成员。Ausiello博士获得了哈佛大学生物化学学士学位和宾夕法尼亚大学的医学博士学位。
Dennis Ausiello,has served as a member of Board of Directors since September 2018. Dr. Ausiello serves as the Director of the Center for Assessment Technology and Continuous Health (CATCH), which he co-founded, Jackson Distinguished Professor of Clinical Medicine at Harvard Medical School and Physician-in-Chief Emeritus at Massachusetts General Hospital. From 1996 to April 2013, Dr. Ausiello served as the Chief of Medicine at Massachusetts General Hospital. Dr. Ausiello is a member of the Institute of Medicine of the National Academy of Sciences and a fellow of the American Academy of Arts and Sciences. Dr. Ausiello has served on the board of directors of Alnylam Pharmaceuticals, Inc., an RNA interference company, since April 2012, the board of directors of Seres Therapeutics, Inc., a microbiome therapeutics company, since April 2015 and previously served on the board of directors of Pfizer Inc., a pharmaceuticals company. Dr. Ausiello received a B.A. in Biochemistry from Harvard College and an M.D. from the University of Pennsylvania. - Dennis Ausiello自2018年9月起担任我们的董事会成员。Ausiello博士担任评估技术和持续健康控制中心的主任，该中心是他共同创立的，哈佛医学院杰克逊临床医学特聘教授和麻省总医院荣休医师。从1996年到2013年4月，Ausiello博士担任麻省总医院的首席医疗官。Ausiello博士是美国国家科学院医学研究所的成员和美国艺术与科学院院士。Ausiello博士自2012年4月起担任AlnylamPharmaceuticals，Inc.（一家RNA干扰公司）的董事会成员，自2015年4月起担任赛里斯治疗公司（一家微生物群治疗公司）的董事会成员，此前曾担任辉瑞公司（一家制药公司）的董事会成员。Ausiello博士获得了哈佛大学生物化学学士学位和宾夕法尼亚大学的医学博士学位。
- Dennis Ausiello,has served as a member of Board of Directors since September 2018. Dr. Ausiello serves as the Director of the Center for Assessment Technology and Continuous Health (CATCH), which he co-founded, Jackson Distinguished Professor of Clinical Medicine at Harvard Medical School and Physician-in-Chief Emeritus at Massachusetts General Hospital. From 1996 to April 2013, Dr. Ausiello served as the Chief of Medicine at Massachusetts General Hospital. Dr. Ausiello is a member of the Institute of Medicine of the National Academy of Sciences and a fellow of the American Academy of Arts and Sciences. Dr. Ausiello has served on the board of directors of Alnylam Pharmaceuticals, Inc., an RNA interference company, since April 2012, the board of directors of Seres Therapeutics, Inc., a microbiome therapeutics company, since April 2015 and previously served on the board of directors of Pfizer Inc., a pharmaceuticals company. Dr. Ausiello received a B.A. in Biochemistry from Harvard College and an M.D. from the University of Pennsylvania.
- Talat Imran
-
Talat Imran自2021年6月起担任我们的董事会成员和首席执行官。2014年1月至2021年6月，Imran先生担任我们的战略副总裁。此前，2007年5月至2021年6月，Imran先生担任Incube Ventures，LP（医疗保健领域的风险投资公司）的合伙人，担任VentureHealth（医疗保健投资公司）的联合创始人兼董事总经理，从2012年12月到2021年6月，担任Venture Web Partners（一家网页设计、开发和托管公司）的首席执行官（从2006年6月到2016年12月）。他在加州大学圣克鲁兹分校获得计算机科学学士学位。
Talat Imran,has served as a member of Board of Directors and Chief Executive Officer since June 2021. From January 2014 to June 2021, Mr. Imran served as Vice President, Strategy. Previously, Mr. Imran served as a partner at InCube Ventures, LP, a venture capital company in the healthcare sector, from May 2007 to June 2021, as co-founder and Managing Director of VentureHealth, a healthcare investment company, from December 2012 to June 2021, and as Chief Executive Officer of Venture Web Partners, a web design, development and hosting firm, from June 2006 to December 2016. He earned a B.A. in Computer Science from the University of California, Santa Cruz. - Talat Imran自2021年6月起担任我们的董事会成员和首席执行官。2014年1月至2021年6月，Imran先生担任我们的战略副总裁。此前，2007年5月至2021年6月，Imran先生担任Incube Ventures，LP（医疗保健领域的风险投资公司）的合伙人，担任VentureHealth（医疗保健投资公司）的联合创始人兼董事总经理，从2012年12月到2021年6月，担任Venture Web Partners（一家网页设计、开发和托管公司）的首席执行官（从2006年6月到2016年12月）。他在加州大学圣克鲁兹分校获得计算机科学学士学位。
- Talat Imran,has served as a member of Board of Directors and Chief Executive Officer since June 2021. From January 2014 to June 2021, Mr. Imran served as Vice President, Strategy. Previously, Mr. Imran served as a partner at InCube Ventures, LP, a venture capital company in the healthcare sector, from May 2007 to June 2021, as co-founder and Managing Director of VentureHealth, a healthcare investment company, from December 2012 to June 2021, and as Chief Executive Officer of Venture Web Partners, a web design, development and hosting firm, from June 2006 to December 2016. He earned a B.A. in Computer Science from the University of California, Santa Cruz.
- Lisa Rometty
-
Lisa Rometty，自2022年1月起担任董事会成员。自2023年8月以来，Rometty女士一直担任Zerigo Health，Inc.的首席执行官和董事会成员，该公司是一家用于家庭治疗慢性皮肤病的数字健康平台。从2020年8月到2022年6月，Rometty女士担任CVS Kidney Care，LLC的总裁，该公司是西维斯健康 Health，Inc.的子公司，专注于创造新的产品和服务，以减缓慢性肾病的进展。2019年7月至2020年8月，Rometty女士在上市生物制药公司Syneos Health担任全球客户解决方案总裁。在此之前，Rometty女士分别于2018年1月至2019年7月以及2015年10月至2017年12月在IBM担任肿瘤学、生命科学和个人健康-沃森健康副总裁兼总经理以及全球市场-沃森健康副总裁兼总经理。Rometty女士拥有密歇根州立大学国际商务学士学位和圣母大学工商管理硕士学位。
Lisa Rometty,has served as a member of Board of Directors since January 2022. Ms. Rometty has been the Chief Executive Officer and a member of the Board of Directors of Zerigo Health, Inc., a digital health platform for the home treatment of chronic skin conditions, since August 2023. From August 2020 to June 2022, Ms. Rometty served as President of CVS Kidney Care, LLC, a subsidiary of CVS Health, Inc. focused on creating new products and services to slow the progression of chronic kidney disease. From July 2019 to August 2020, Ms. Rometty served as President, Global Client Solutions at Syneos Health, a public biopharmaceutical company. Prior to that, Ms. Rometty served as Vice President and General Manager of Oncology, Life Sciences and Personal Health-Watson Health and as Vice President and General Manager, Global Markets-Watson Health at IBM from January 2018 to July 2019 and October 2015 to December 2017, respectively. Ms. Rometty holds a B.S. in International Business from Michigan State University and an M.B.A. from the University of Notre Dame. - Lisa Rometty，自2022年1月起担任董事会成员。自2023年8月以来，Rometty女士一直担任Zerigo Health，Inc.的首席执行官和董事会成员，该公司是一家用于家庭治疗慢性皮肤病的数字健康平台。从2020年8月到2022年6月，Rometty女士担任CVS Kidney Care，LLC的总裁，该公司是西维斯健康 Health，Inc.的子公司，专注于创造新的产品和服务，以减缓慢性肾病的进展。2019年7月至2020年8月，Rometty女士在上市生物制药公司Syneos Health担任全球客户解决方案总裁。在此之前，Rometty女士分别于2018年1月至2019年7月以及2015年10月至2017年12月在IBM担任肿瘤学、生命科学和个人健康-沃森健康副总裁兼总经理以及全球市场-沃森健康副总裁兼总经理。Rometty女士拥有密歇根州立大学国际商务学士学位和圣母大学工商管理硕士学位。
- Lisa Rometty,has served as a member of Board of Directors since January 2022. Ms. Rometty has been the Chief Executive Officer and a member of the Board of Directors of Zerigo Health, Inc., a digital health platform for the home treatment of chronic skin conditions, since August 2023. From August 2020 to June 2022, Ms. Rometty served as President of CVS Kidney Care, LLC, a subsidiary of CVS Health, Inc. focused on creating new products and services to slow the progression of chronic kidney disease. From July 2019 to August 2020, Ms. Rometty served as President, Global Client Solutions at Syneos Health, a public biopharmaceutical company. Prior to that, Ms. Rometty served as Vice President and General Manager of Oncology, Life Sciences and Personal Health-Watson Health and as Vice President and General Manager, Global Markets-Watson Health at IBM from January 2018 to July 2019 and October 2015 to December 2017, respectively. Ms. Rometty holds a B.S. in International Business from Michigan State University and an M.B.A. from the University of Notre Dame.
- Vasudev Bailey
-
Vasudev Bailey，自2025年1月起担任专注于医疗保健技术和人工智能的风险投资公司Anomaly Ventures的创始人和普通合伙人。2017年2月至2024年10月，Bailey博士在ARTIS Ventures担任高级合伙人，领导生命科学和数字健康领域的投资。在其职业生涯的早期，贝利博士创立并领导了多家公司，其中包括GLG研究所，该研究所已成为全球最大的CEO和CXO网络。他还曾在麦肯锡公司担任管理顾问，为医疗保健和生命科学行业的客户提供建议。贝利博士从养老金、捐赠基金和家族办公室筹集和管理资金，目前在约翰霍普金斯大学和加州大学欧文分校的顾问委员会任职。贝利博士曾在生物技术和生命科学公司的多元化投资组合中担任过各种治理职务，重点是前沿疗法和诊断。他的董事会和观察员角色涵盖早期企业和成长期公司，反映了对公司组建、战略发展和科学创新的深度参与。Bailey博士在加州大学欧文分校获得辅修政治学的生物医学工程学士学位，在约翰霍普金斯医学院获得博士学位，并被公认为Siebel学者、美敦力学者和Regents学者。
Vasudev Bailey,has served as the Founder and General Partner of Anomaly Ventures, a venture capital firm focused on healthcare technology and artificial intelligence, since January 2025. From February 2017 to October 2024, Dr. Bailey served as a Senior Partner at ARTIS Ventures, where he led investments across the life sciences and digital health sectors. Earlier in his career, Dr. Bailey founded and led multiple companies, including the GLG Institute, which became the largest global network of CEOs and CXOs. He also served as a management consultant at McKinsey & Company, advising clients in the healthcare and life sciences industries. Dr. Bailey has raised and managed capital from pensions, endowments, and family offices, and currently serves on advisory boards at Johns Hopkins University and the University of California, Irvine. Dr. Bailey has served in various governance capacities across a diverse portfolio of biotechnology and life sciences companies, with a focus on cutting-edge therapeutics and diagnostics. His board and observer roles span early-stage ventures and growth-stage companies, reflecting deep engagement in company formation, strategic development, and scientific innovation. Dr. Bailey obtained his B.S. in Biomedical Engineering with a minor in Political Science from the University of California, Irvine, his Ph.D. from the Johns Hopkins School of Medicine and has been recognized as a Siebel Scholar, Medtronic Scholar, and Regents Scholar. - Vasudev Bailey，自2025年1月起担任专注于医疗保健技术和人工智能的风险投资公司Anomaly Ventures的创始人和普通合伙人。2017年2月至2024年10月，Bailey博士在ARTIS Ventures担任高级合伙人，领导生命科学和数字健康领域的投资。在其职业生涯的早期，贝利博士创立并领导了多家公司，其中包括GLG研究所，该研究所已成为全球最大的CEO和CXO网络。他还曾在麦肯锡公司担任管理顾问，为医疗保健和生命科学行业的客户提供建议。贝利博士从养老金、捐赠基金和家族办公室筹集和管理资金，目前在约翰霍普金斯大学和加州大学欧文分校的顾问委员会任职。贝利博士曾在生物技术和生命科学公司的多元化投资组合中担任过各种治理职务，重点是前沿疗法和诊断。他的董事会和观察员角色涵盖早期企业和成长期公司，反映了对公司组建、战略发展和科学创新的深度参与。Bailey博士在加州大学欧文分校获得辅修政治学的生物医学工程学士学位，在约翰霍普金斯医学院获得博士学位，并被公认为Siebel学者、美敦力学者和Regents学者。
- Vasudev Bailey,has served as the Founder and General Partner of Anomaly Ventures, a venture capital firm focused on healthcare technology and artificial intelligence, since January 2025. From February 2017 to October 2024, Dr. Bailey served as a Senior Partner at ARTIS Ventures, where he led investments across the life sciences and digital health sectors. Earlier in his career, Dr. Bailey founded and led multiple companies, including the GLG Institute, which became the largest global network of CEOs and CXOs. He also served as a management consultant at McKinsey & Company, advising clients in the healthcare and life sciences industries. Dr. Bailey has raised and managed capital from pensions, endowments, and family offices, and currently serves on advisory boards at Johns Hopkins University and the University of California, Irvine. Dr. Bailey has served in various governance capacities across a diverse portfolio of biotechnology and life sciences companies, with a focus on cutting-edge therapeutics and diagnostics. His board and observer roles span early-stage ventures and growth-stage companies, reflecting deep engagement in company formation, strategic development, and scientific innovation. Dr. Bailey obtained his B.S. in Biomedical Engineering with a minor in Political Science from the University of California, Irvine, his Ph.D. from the Johns Hopkins School of Medicine and has been recognized as a Siebel Scholar, Medtronic Scholar, and Regents Scholar.
高管简历
中英对照 | 中文 | 英文- Talat Imran
Talat Imran自2021年6月起担任我们的董事会成员和首席执行官。2014年1月至2021年6月，Imran先生担任我们的战略副总裁。此前，2007年5月至2021年6月，Imran先生担任Incube Ventures，LP（医疗保健领域的风险投资公司）的合伙人，担任VentureHealth（医疗保健投资公司）的联合创始人兼董事总经理，从2012年12月到2021年6月，担任Venture Web Partners（一家网页设计、开发和托管公司）的首席执行官（从2006年6月到2016年12月）。他在加州大学圣克鲁兹分校获得计算机科学学士学位。
Talat Imran,has served as a member of Board of Directors and Chief Executive Officer since June 2021. From January 2014 to June 2021, Mr. Imran served as Vice President, Strategy. Previously, Mr. Imran served as a partner at InCube Ventures, LP, a venture capital company in the healthcare sector, from May 2007 to June 2021, as co-founder and Managing Director of VentureHealth, a healthcare investment company, from December 2012 to June 2021, and as Chief Executive Officer of Venture Web Partners, a web design, development and hosting firm, from June 2006 to December 2016. He earned a B.A. in Computer Science from the University of California, Santa Cruz.- Talat Imran自2021年6月起担任我们的董事会成员和首席执行官。2014年1月至2021年6月，Imran先生担任我们的战略副总裁。此前，2007年5月至2021年6月，Imran先生担任Incube Ventures，LP（医疗保健领域的风险投资公司）的合伙人，担任VentureHealth（医疗保健投资公司）的联合创始人兼董事总经理，从2012年12月到2021年6月，担任Venture Web Partners（一家网页设计、开发和托管公司）的首席执行官（从2006年6月到2016年12月）。他在加州大学圣克鲁兹分校获得计算机科学学士学位。
- Talat Imran,has served as a member of Board of Directors and Chief Executive Officer since June 2021. From January 2014 to June 2021, Mr. Imran served as Vice President, Strategy. Previously, Mr. Imran served as a partner at InCube Ventures, LP, a venture capital company in the healthcare sector, from May 2007 to June 2021, as co-founder and Managing Director of VentureHealth, a healthcare investment company, from December 2012 to June 2021, and as Chief Executive Officer of Venture Web Partners, a web design, development and hosting firm, from June 2006 to December 2016. He earned a B.A. in Computer Science from the University of California, Santa Cruz.
- Svai Sanford
Svai Sanford自2018年11月起担任公司首席财务官。加入我们之前，从2017年6月到2018年11月，Sanford先生担任消费者皮肤护理公司PH Pharma Inc.的执行顾问和代理首席财务官。从2015年9月到2017年3月，他担任SFJ Pharmaceuticals，Inc.（一家药物开发公司）的首席财务官，从2012年7月到2015年9月，他担任Vivus，Inc.（一家上市生物制药公司）的首席财务官兼首席会计官。从1996年到2002年，Sanford先生是KPMG LLP的审计业务的成员。他在堪萨斯州立大学（Kansas State University）获得会计学学士学位，是一名不活跃的注册会计师。
Svai Sanford,has served as Chief Financial Officer since November 2018. Prior to joining the Company, from June 2017 to November 2018, Mr. Sanford served as an executive consultant and acting Chief Financial Officer for pH Pharma Inc., a consumer skin care company. From September 2015 to March 2017, he served as the Chief Financial Officer of SFJ Pharmaceuticals, Inc., a drug development company, and from July 2012 to September 2015, he served as the Chief Financial Officer and Chief Accounting Officer of VIVUS, Inc., a public biopharmaceutical company. Mr. Sanford was a member of the audit practice at KPMG LLP from 1996 to 2002. He earned a B.S. in Accounting from Kansas State University and is a Certified Public Accountant (inactive).- Svai Sanford自2018年11月起担任公司首席财务官。加入我们之前，从2017年6月到2018年11月，Sanford先生担任消费者皮肤护理公司PH Pharma Inc.的执行顾问和代理首席财务官。从2015年9月到2017年3月，他担任SFJ Pharmaceuticals，Inc.（一家药物开发公司）的首席财务官，从2012年7月到2015年9月，他担任Vivus，Inc.（一家上市生物制药公司）的首席财务官兼首席会计官。从1996年到2002年，Sanford先生是KPMG LLP的审计业务的成员。他在堪萨斯州立大学（Kansas State University）获得会计学学士学位，是一名不活跃的注册会计师。
- Svai Sanford,has served as Chief Financial Officer since November 2018. Prior to joining the Company, from June 2017 to November 2018, Mr. Sanford served as an executive consultant and acting Chief Financial Officer for pH Pharma Inc., a consumer skin care company. From September 2015 to March 2017, he served as the Chief Financial Officer of SFJ Pharmaceuticals, Inc., a drug development company, and from July 2012 to September 2015, he served as the Chief Financial Officer and Chief Accounting Officer of VIVUS, Inc., a public biopharmaceutical company. Mr. Sanford was a member of the audit practice at KPMG LLP from 1996 to 2002. He earned a B.S. in Accounting from Kansas State University and is a Certified Public Accountant (inactive).
- Mir Hashim
Mir Hashim自2013年6月起担任我们的首席科学官，并于2013年6月至2021年6月担任我们的董事会成员。Hashim博士自2008年9月起担任Incube Labs，LLC（一家医疗设备研究公司）副总裁、研究与开发。在此之前，他在GlaxoSmithKline plc（一家全球制药公司）担任了18年的多个科学职务，包括药理学主管。哈希姆博士在奥斯马尼亚大学获得生物学和化学学士学位，在海得拉巴大学获得生命科学硕士学位，在纽芬兰纪念大学医学院获得药理学博士学位。
Mir Hashim,has served as Chief Scientific Officer since June 2013 and was a member of board of directors from June 2013 to June 2021. Dr. Hashim has served as Vice President, Research and Development, at InCube Labs, LLC, a medical device research company, since September 2008. Prior to this, he spent 18 years serving in multiple scientific roles at GlaxoSmithKline plc, a global pharmaceutical company, including as Head of Pharmacology. Dr. Hashim earned a B.S. in Biology and Chemistry from Osmania University, a M.S. in Life Sciences from the University of Hyderabad and a Ph.D. in Pharmacology from the School of Medicine, Memorial University of Newfoundland.- Mir Hashim自2013年6月起担任我们的首席科学官，并于2013年6月至2021年6月担任我们的董事会成员。Hashim博士自2008年9月起担任Incube Labs，LLC（一家医疗设备研究公司）副总裁、研究与开发。在此之前，他在GlaxoSmithKline plc（一家全球制药公司）担任了18年的多个科学职务，包括药理学主管。哈希姆博士在奥斯马尼亚大学获得生物学和化学学士学位，在海得拉巴大学获得生命科学硕士学位，在纽芬兰纪念大学医学院获得药理学博士学位。
- Mir Hashim,has served as Chief Scientific Officer since June 2013 and was a member of board of directors from June 2013 to June 2021. Dr. Hashim has served as Vice President, Research and Development, at InCube Labs, LLC, a medical device research company, since September 2008. Prior to this, he spent 18 years serving in multiple scientific roles at GlaxoSmithKline plc, a global pharmaceutical company, including as Head of Pharmacology. Dr. Hashim earned a B.S. in Biology and Chemistry from Osmania University, a M.S. in Life Sciences from the University of Hyderabad and a Ph.D. in Pharmacology from the School of Medicine, Memorial University of Newfoundland.
- Eric Groen
Eric Groen，自2025年7月起担任Genelux Corporation总法律顾问、公司秘书、首席合规官和业务发展主管。在加入Genelux Corporation之前，Groen先生于2021年7月至2025年5月期间担任临床阶段的上市生物技术公司Rani Therapeutics Holdings, Inc.的总法律顾问。Groen先生还于2022年2月至2023年5月在Rani Therapeutics领导业务发展。在此之前，从2001年9月到2021年7月，Groen先生在全球生物技术公司安进公司担任过各种国内和国际角色，职责不断增加，包括领导负责业务发展交易、运营和制造以及临床试验的法律团队。他还曾担任安进在加拿大、拉丁美洲、中东和非洲的商业业务的区域总法律顾问。从1999年1月到2001年8月，Groen先生在HealthNet担任公司法律顾问，HealthNet是一家管理式医疗和其他医疗保健实体的公共控股公司。在此之前，Groen先生是TroyGould律师事务所的合伙人。Groen先生获得了加州大学圣巴巴拉分校政治学学士学位和哈佛大学法学院法学博士学位。
Eric Groen,has served as Genelux Corporation General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development since July 2025. Prior to joining Genelux Corporation , Mr. Groen served as general counsel for Rani Therapeutics Holdings, Inc., a clinical-stage, public biotechnology company, from July 2021 to May 2025. Mr. Groen also led business development at Rani Therapeutics from February 2022 to May 2023. Previously, from September 2001 to July 2021, Mr. Groen served in various domestic and international roles of increasing responsibility at Amgen Inc., a global biotechnology company, including leading the legal teams responsible for business development transactions, operations and manufacturing, and clinical trials. He also served as regional general counsel to Amgen's commercial business in Canada, Latin America, Middle East and Africa. From January 1999 to August 2001, Mr. Groen was corporate counsel at HealthNet, a public holding company of managed care and other healthcare entities. Prior to that, Mr. Groen was an associate at the law firm of TroyGould. Mr. Groen earned a B.A. in Political Science from the University of California, Santa Barbara and a J.D. from Harvard Law School.- Eric Groen，自2025年7月起担任Genelux Corporation总法律顾问、公司秘书、首席合规官和业务发展主管。在加入Genelux Corporation之前，Groen先生于2021年7月至2025年5月期间担任临床阶段的上市生物技术公司Rani Therapeutics Holdings, Inc.的总法律顾问。Groen先生还于2022年2月至2023年5月在Rani Therapeutics领导业务发展。在此之前，从2001年9月到2021年7月，Groen先生在全球生物技术公司安进公司担任过各种国内和国际角色，职责不断增加，包括领导负责业务发展交易、运营和制造以及临床试验的法律团队。他还曾担任安进在加拿大、拉丁美洲、中东和非洲的商业业务的区域总法律顾问。从1999年1月到2001年8月，Groen先生在HealthNet担任公司法律顾问，HealthNet是一家管理式医疗和其他医疗保健实体的公共控股公司。在此之前，Groen先生是TroyGould律师事务所的合伙人。Groen先生获得了加州大学圣巴巴拉分校政治学学士学位和哈佛大学法学院法学博士学位。
- Eric Groen,has served as Genelux Corporation General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development since July 2025. Prior to joining Genelux Corporation , Mr. Groen served as general counsel for Rani Therapeutics Holdings, Inc., a clinical-stage, public biotechnology company, from July 2021 to May 2025. Mr. Groen also led business development at Rani Therapeutics from February 2022 to May 2023. Previously, from September 2001 to July 2021, Mr. Groen served in various domestic and international roles of increasing responsibility at Amgen Inc., a global biotechnology company, including leading the legal teams responsible for business development transactions, operations and manufacturing, and clinical trials. He also served as regional general counsel to Amgen's commercial business in Canada, Latin America, Middle East and Africa. From January 1999 to August 2001, Mr. Groen was corporate counsel at HealthNet, a public holding company of managed care and other healthcare entities. Prior to that, Mr. Groen was an associate at the law firm of TroyGould. Mr. Groen earned a B.A. in Political Science from the University of California, Santa Barbara and a J.D. from Harvard Law School.
- Kate McKinley
Kate McKinley，自2023年5月起担任首席商务官。McKinley女士在生物制药行业拥有超过20年的经验，包括担任行政领导和董事会董事。在加入公司之前，从2022年7月到2023年5月，麦金利女士担任Spark Outcomes的首席执行官。在此之前，McKinley女士于2021年7月至2022年7月担任Elevar Therapeutics，Inc.（前身为LSK Biopharma，Inc.）的首席执行官，此前曾于2019年1月至2021年5月担任Elevar的首席商务官和首席商务官。McKinley女士的职业生涯始于艾伯维公司和雅培公司，在那里她担任泌尿外科、肿瘤科和妇科领域的全国销售副总裁。她以优异成绩毕业于塔尔萨大学。她拥有该大学柯林斯商学院的工商管理硕士学位和市场营销和管理学位的工商管理学士学位，并辅修心理学。
Kate McKinley,has served as Chief Business Officer since May 2023. Ms. McKinley has over 20 years of experience in the bio-pharmaceutical industry, including positions in executive leadership and as a board director. Prior to joining the Company, from July 2022 through May 2023, Ms. McKinley was Chief Executive Officer of Spark Outcomes. Prior to this, Ms. McKinley was Chief Executive Officer of Elevar Therapeutics, Inc. (formerly known as LSK Biopharma, Inc.) from July 2021 to July 2022, having previously been Elevar's Chief Commercial Officer and Chief Business Officer from January 2019 to May 2021. Ms. McKinley began her career at Abbvie Inc. and Abbott Laboratories, Inc. where she served as Vice President of National Sales in the urology, oncology, and gynecology space. She is a summa cum laude graduate of The University of Tulsa. She holds an M.B.A. from the university's Collins College of Business and a B.S. in Business Administration with degrees in Marketing and Management, and a minor in Psychology.- Kate McKinley，自2023年5月起担任首席商务官。McKinley女士在生物制药行业拥有超过20年的经验，包括担任行政领导和董事会董事。在加入公司之前，从2022年7月到2023年5月，麦金利女士担任Spark Outcomes的首席执行官。在此之前，McKinley女士于2021年7月至2022年7月担任Elevar Therapeutics，Inc.（前身为LSK Biopharma，Inc.）的首席执行官，此前曾于2019年1月至2021年5月担任Elevar的首席商务官和首席商务官。McKinley女士的职业生涯始于艾伯维公司和雅培公司，在那里她担任泌尿外科、肿瘤科和妇科领域的全国销售副总裁。她以优异成绩毕业于塔尔萨大学。她拥有该大学柯林斯商学院的工商管理硕士学位和市场营销和管理学位的工商管理学士学位，并辅修心理学。
- Kate McKinley,has served as Chief Business Officer since May 2023. Ms. McKinley has over 20 years of experience in the bio-pharmaceutical industry, including positions in executive leadership and as a board director. Prior to joining the Company, from July 2022 through May 2023, Ms. McKinley was Chief Executive Officer of Spark Outcomes. Prior to this, Ms. McKinley was Chief Executive Officer of Elevar Therapeutics, Inc. (formerly known as LSK Biopharma, Inc.) from July 2021 to July 2022, having previously been Elevar's Chief Commercial Officer and Chief Business Officer from January 2019 to May 2021. Ms. McKinley began her career at Abbvie Inc. and Abbott Laboratories, Inc. where she served as Vice President of National Sales in the urology, oncology, and gynecology space. She is a summa cum laude graduate of The University of Tulsa. She holds an M.B.A. from the university's Collins College of Business and a B.S. in Business Administration with degrees in Marketing and Management, and a minor in Psychology.